News and ViewsRecent Price Movement and Market Comparison
Beryl Drugs has been on a downward trajectory over multiple time frames. In the past week, the stock has fallen by 4.23%, contrasting with the Sensex’s modest gain of 0.91%. Over the last month, the decline deepened to 5.23%, while the Sensex retreated by 2.49%. Year-to-date, the stock has lost 10.09%, significantly underperforming the Sensex’s 2.24% decline. The most striking contrast is seen over the one-year period, where Beryl Drugs has plummeted nearly 40%, whereas the Sensex has appreciated by 6.44%. Despite this recent weakness, the stock has delivered strong long-term returns, with gains of 58.20% over three years and an impressive 164.65% over five years, outperforming the Sensex’s respective 36.94% and 64.22% gains.
